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The synthesis, cytotoxicity, anti-leishmanial and anti-trypanosomal activities of twelve triclosan-caffeic 
acid hybrids are described herein. The structure of the synthesized products was elucidated by a 
combination of spectrometric analyses. The synthesized compounds were evaluated against 
amastigotes forms of L. (V) panamensis, which is the most prevalent Leishmania species in Colombia, 
and against Trypanosoma cruzi, which is the pathogenic species to humans. Cytotoxicity was evaluated 
against human U-937 macrophages. Eight compounds were active against L. (V) panamensis (18-23, 26 
and 30) and eight of them against T. cruzi (19-22, 24 and 28-30) with EC50 values lower than 40 µM. 
Compounds 19-22, 24 and 28-30 showed higher activities than benznidazole (BNZ). Esters 19 and 21 
were the most active compounds for both L. (V) panamensis and T. cruzi with 3.82 and 11.65 µM and 
8.25 and 8.69 µM, respectively. Compounds 19-22, 24 and 28-30 showed higher activities than 
benznidazole (BNZ). Most of the compounds showed antiprotozoal activity and with exception of 18, 
26 and 28, the remaining compounds were toxic for mammalian cells, yet they have potential to be 
considered as candidates for anti-trypanosomal and anti-leishmanial drug development. The activity is 
dependent on the length of the alkyl linker with compound 19, bearing a four-carbon alkyl chain, the 
most performing hybrid. In general, hydroxyl groups increase both activity and cytotoxicity and the 
presence of the double bond in the side chain is not decisive for cytotoxicity and anti-protozoal activity.  
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Leishmaniasis and Chagas disease are a cause of mortality in various developing countries of tropical 
and subtropical regions. These diseases are endemic health problems in developing countries. This 
situation is aggravated by increasing treatment failures with available drugs [1]. Leishmaniasis involves 
a wide spectrum of clinical manifestations ranging from small cutaneous nodules, plaques or ulcers 
(cutaneous leishmaniasis), to severe mucosal tissue destruction (mucosal leishmaniasis) or disfunction 
of vital organs and tissues such as liver, spleen and bone marrow (visceral leishmaniasis). This disease 
affects to more than 12 million people worldwide and is caused by various species of the Leishmania 
genus that include L. panamensis, L. braziliensis and L. guayanensis (members of the Viannia 
subgenus), as well as L. mexicana and L. amazonensis (members of the Leishmania subgenus). L. (V) 
panamensis is one of the most prevalent leishmania species involved in human cases of cutaneous 
leishmaniasis in Colombia [2]. On the other hand, Chagas disease, also named American 
trypanosomiasis, affects about 10 million people mainly in Latin America. This disease is produced by 
the protozoan parasite Trypanosoma cruzi that is transmitted to the mammalian host through the phases 
of triatomine bugs belonging to Triatoma, Rhodnius and Panstrongylus genus [3].  
Current chemotherapies to treat cutaneous leishmaniasis are based on old drugs, such as pentavalent 
antimonials, meglumine antimoniate (MA) and for the treatment of Chagas disease sodium 
stibogluconate (SSG) and nitroaromatic compounds, such as benznidazole (BNZ) and nifurtimox (NF), 
are usually prescribed. Unfortunately, all of these drugs have severe toxic effects on patients which are 
associated with high doses and lengths of therapeutic schemes. Moreover, they are no longer as 
effective as before due to the emergence of drug resistance in the parasite, which is complicating the 
treatment of these parasitic diseases. [4-6].  
Caffeic acid and some of its esters and amides derivatives exhibit a broad spectrum of biological 
activities including anti-inflammatory [7], antimicrobial [8,9], antioxidant [10], anti-Alzheimer [11], 
analgesic [12] and anticancer effects [13-15]. In addition, some studies have shown that caffeic acid 
esters have high anti-leishmanial activity [16-19]. Three caffeic acid esters (1-3, see figure 1), which 
have been isolated from leaves of Piper sanguineispicum, showed anti-leishmanial activity with an IC50 
of 2.0, 10 and 1.8 μM, respectively. In addition, these compounds exhibited moderate cytotoxicity on 
murine macrophages [16]. The alkyl caffeic acid ester (4) was active against axenic amastigotes of L. 
panamensis with an EC50 of 0.67 µM although this compound was toxic for mammalian cells [17]. The 
caffeic acid derivative (5), isolated from V. wallichii, showed an IC50 value of 48.8 μM against L. 
major promastigotes and high cytotoxicity against a J774.1 cell line [18]. Rosmarinic acid (6) exhibited 
anti-leishmanial activity against both L. major and L. donovani (IC50 of 59.2 and 74.4 μM, 
respectively) [19]. Isopentyl caffeate (7) showed anti-trypanosomal activity against T. brucei 
bloodstream forms with a minimum inhibitory concentration (MIC) of 0.31 μg/ml [20]. Finally, 




Figure 1. Caffeic acid esters and triclosan derivatives with anti-protozoal activity. 
 
Triclosan is a non-competitive inhibitor of purified enoyl-acyl carrier protein reductase (ENR) which 
has demonstrated inhibitory in vitro activity against Plasmodium falciparum [22–25]. A previous study 
showed that triclosan and triclosan-quinoline hybrids bearing a propyl linker (see compound 9 in figure 
1) have in vitro activity against axenic and intracellular amastigotes of L. panamensis with an effective 
concentration (EC50) below 24 µg/mL [26]. Triclosan-chalcone hybrids with spacers of three (10), four 
(11) and five (12) methylene units were active against leishmania parasites (EC50 9.4, 10.2 and 13.5 
µg/mL, respectively) and showed no toxicity towards mammalian cells (>200 µg/mL) [27] (see Figure 
1). 
An emerging strategy in medicinal chemistry and drug discovery relies in the use of hybrid molecules 
which results from the covalent linking of two molecules with individual intrinsic pharmacological 
activity [28,29]. Hybrid molecules bear two distinct pharmacophores with different biological functions 
and may display dual activity although both entities of the hybrid molecule are not necessarily acting 
on the same biological target. [30-32]. In the search for new therapeutic alternatives to treat cutaneous 
leishmaniasis and Chagas disease we have designed and synthesized a series of new triclosan-caffeic 
acid hybrids (see structures in Figure 2) and we have evaluated their in vitro cytotoxicity, anti-
leishmanial and anti-trypanosomal activities. 
 
 
Figure 2. Design of triclosan-caffeic acid hybrids as antiprotozoal agents. 
 
2. Results and discussion 
2.1. Chemistry 
The synthetic strategy for the preparation of caffeic acid esters is shown in Scheme 1. Thus, reaction of 
triclosan 1 with ɷ-bromoalkylalcohols upon microwave assisted Williamson etherification [27]  
yielded alcohols 2-8 in 61-88%. Caffeic acid silylation with TBSCl afforded silyl-protected caffeic acid 
10 upon microwave irradiation [38]. This compound was esterified with ɷ-bromoalkylalcohols in the 
presence of EDC and DMAP to provide protected esters 11-17 in 41-60% yields [33]. Deprotection 
with TBAF and benzoic acid gave rise to esters 18-24 in 50-92% yields [34]. Attempts to directly 
obtain these compounds by coupling caffeic acid 9 with alcohols 2-8 using different coupling agents, 
such as EDC/HOBt [35], DCC/HOBt [36] and BOP/Et3N [37], were fruitless. On the other hand, 
reaction of methylated caffeic acid 25 with thionyl chloride generated the corresponding acid chloride 
which in turn was reacted with alcohols 2, 3, 5 and 7 to afford esters 26-29 in 40-60% yields. 
Compound 30 was obtained in 94% yield by catalytic hydrogenation of compound 26 [39].  
The structures of all compounds have been established by a combined study of IR, ESI-MS, 1H-NMR, 
13C-NMR and COSY spectra. IR spectra exhibit characteristic absorption peaks corresponding to C=O, 
C=C, C=CAr, C-O-C, C-HAr and C-Cl groups. ESI-MS spectra show characteristic [M+Na]+ peaks 
corresponding to their molecular weights. The assignments of all the signals to individual H or C-atoms 
have been performed on the basis of typical δ-values and J-constants. The 1H-NMR spectra of these 
compounds dissolved in CDCl3 or CD3OD show signals of –CH2O-  (∼4.06 ppm), H-C=C-Htrans (∼6.21 
and 7.50 ppm), -C = C-Htriclosan ring (∼6.92 and 7.46 ppm). 13C-NMR spectra show signals around 62, 
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Scheme 1. Synthetic pathway to triclosan-caffeic acid hybrids. 
2.2. Biological activities 
The effect of triclosan-caffeic acid hybrids on cell growth and viability was assessed in human 
macrophages (U-937 cells) which are the host cells for L. (V) panamensis and T. cruzi parasites. In 
addition, the antiparasite activity of these compounds was tested on intracellular amastigotes of L. (V.) 
panamensis and T. cruzi according to the ability of these compounds to reduce the amount of parasite 
inside infected macrophages. Results are summarized in Table 1. 




on U-937 cells 
Anti-leishmanial activity 
on intracellular amastigotes 
 
 
 Anti-trypanosomal activity 
on intracellular amastigotes 
 
 
LC50 (Mean ± SEM) [µM]a EC50 (Mean ± SEM) [µM]b SIc  EC50 (Mean ± SEM) [µM] SI 
18  >392.34 24.34 + 0.31  >16.12  52.42 + 5.04  >7.48 
19 12.03 + 0.77  3.82 + 0.19  3.16  8.25 + 1.21  1.46 
20 8.18 + 0.02  15.30 + 0.17  0.53  29.66 + 1.81  0.28 
21 19.97 + 1.9  11.65 + 1.58  1.72  8.69 + 0.62  2.29 
22 40.18 + 3.81  12.92 + 3.41  3.11  18.35 + 0.54  2.19 
23 3.62 + 0.35  30.22 + 1.74  0.12  41.32 + 3.87  0.09 
24 173.74 + 30.12  42.55 + 0.80  4.08  34.21 + 2.74  5.08 
26 >371.87 38.06 + 1.77  >9.77  >37.19 <10 
27 73.39 + 8.55  53.19 + 4.18  1.38  42.77 + 7.50  1.72 
28  336.75 99.05 + 5.93  >3.40  27.44 + 5.93   >12.26 
29 106.92 + 10.48  48.46 + 2.16  2.21  33.02 + 3.94  3.24 
30 249.52 + 9.66  40.25 + 9.03  6.20  33.29 + 0.52  7.49 
Triclosan  193.41 + 32.86  38.61 + 2.38  5.01  48.97 + 4.21  3.95 
Caffeic acid 1110.12 1103.46 + 177.34  >1.0  156.92 + 18.43  >7.07 
Amphotericin B  45.6 + 2.2  0.054 + 0.011  842  NAd - 
Benznidazole 687.8 ± 16.1  NAd -  40.3 ± 6.92  17.0 
 
Data represent, mean value +/- standard deviation; a LC50: Lethal Concentration 50 in μM; b EC50: Effective 
Concentration 50 in μM; c SI: Selectivity Index = LC50 / EC50; dNA: Not applicable. 
 
All compounds, with exception of 18, 26, 28 and caffeic acid, were cytotoxic to U-937 cells showing 
LC50 < 200.0 μM. Compound 30 showed moderate cytotoxicity (LC50 > 200.0 μM) while compounds 
18, 26, 28, caffeic acid and benznidazole had no cytotoxicity (LC50 > 300 μM). In turn, amphotericin B 
showed high cytotoxicity (LC50 = 45.6 μM) (Table 1).  
The anti-leishmanial and anti-trypanosomal activities were measured by determining the effective 
concentration 50 (EC50) that corresponds to the concentration of drug that gives the half-maximal 
reduction of the parasite growth (Table 1). Dose-response relationship shows that compounds 18-23, 
26, 30 and triclosan were active against intracellular amastigotes of L. (V) panamensis with EC50 < 40 
μM. The most actives esters are 18-22, with an EC50 of 24.34 µM, 3.82 µM, 15.30 µM, 11.65 µM and 
12.92 µM, respectively, followed by 23, 26 and 30 with an EC50 of 30.22 µM, 38.06 µM and 40.25 
µM, respectively. As expected, the anti-leishmanial drug amphotericin B showed activity with low 
EC50 values. In turn, compounds 19, 21, and 22 were highly active against intracellular amastigotes of 
T. cruzi (Tulahuen strain expressing β-galactosidase) with EC50 of 8.25 µM, 8.69 µM and 18.35 µM, 
respectively, followed by compounds 20, 24 and 28-30 with an EC50 of 29.66 µM, 34.21 µM, 27.44 
µM, 33.02 µM and 33.29, respectively. In this case, benznidazole showed activity with an EC50 of 40.3 
µM. Esters 19-22, 24 and 28-30 displayed higher anti-trypanosomal activity than benznidazole. 
However, the SI of these compounds is affected by their cytotoxicity. These results suggest a selective 
biological activity of the hybrids reported here (with the exception of 20 and 23) as being more active 
against T. cruzi parasites (Tulahuen strain expressing β-galactosidase) than against U-937 cells.  
It can be deduced form table 1 that the activity is related to the length of the alkyl chains and to the 
even or odd number of carbon atoms of these chains. Thus, for an even number of carbons a decrease 
in activity was observed with increasing linker length (19 vs 22 and 24). In contrast, for an odd number 
of carbons an increase in activity was achieved with increasing linker length (18 vs 20 and 21). The 
four-carbon alkyl chain was the most determinant for the activity, as compound 19 was the most 
performing one in both L. (V) panamensis and T. cruzi parasites. The presence of hydroxyl groups 
increases cytotoxicity and anti-leishmanial and anti-trypanosomal activities (18, 19, 21, 23 vs. 26-29). 
This result is in agreement with the reports for several chalcones and coumarins [40,41]. However, the 
presence of hydroxyl groups decreased the activity of some of these compounds (26, 29 vs 18, 23) 
when they were evaluated against T. cruzi (Tulahuen strain expressing β-galactosidase). The effect of 
the hydroxyl groups may be due to a better molecular recognition ability towards target bioreceptors 
upon hydrogen bond formation [42]. It is interesting to note the synergistic effect of the parent subunits 
in the hybrids in comparison with the unlinked cases. For example, triclosan is less active against L. 
(V). panamensis and T. cruzi than its hybrids 19-22. This phenomenon can also be observed for all 
hybrids, as they show increased activity compared to caffeic acid. 
 
On the other hand, the presence of a double bond in the side chain is not decisive for cytotoxicity and 
anti-protozoal activity (26 vs. 30). A similar result was found for cinnamic acid bornyl ester and its 
hydrogenated derivative (39.6 and 50.2 µM, respectively) [43]. However, we have previously reported 
on cinnamic acid alkyl ester derivatives and we have shown a decrease in activity upon saturation of 
the double bond of these molecules [19]. Based on this fact, we proposed as their mechanism of action 
a nucleophilic addition of amino acid residues on the Michael acceptor system of these compounds [19, 
44, 45]. However, according to the results achieved in this work we can suggest that the activity of 
triclosan-caffeic acid hybrids could be due to the presence of the triclosan unit. Two mechanisms of 
action for similar compounds have been reported. The first one could be related with the inhibition of 
the enzymatic systems of the protozoan by blocking the utilization of iron by the parasite, a mode of 
action which was observed for the African species [46]. The second one could be related with the loss 
of mitochondrial transmembrane potential [47].  
 
3. Conclusions 
The synthesis, cytotoxicity and activity against L. (V) panamensis and T. cruzi amastigotes of twelve 
triclosan-caffeic acid hybrids are reported. Eight of them were active against L. (V) panamensis (18-23, 
26 and 30) and eigth of them against T. cruzi (19-22, 24 and 28-30) with EC50 values lower than 40 
µM, with 19 and 21 being the most active compounds against both L. (V) panamensis and T. cruzi with 
3.82 and 11.65 µM and 8.25 and 8.69 µM, respectively. Compounds 19-22, 24 and 28-30 showed 
higher activities than benznidazole (BNZ). Studies on an animal model of leishmaniasis are needed to 
confirm the results observed in vitro. Except for 18, 26 and 28, most of the compounds showed 
antiprotozoal activity but were toxic for mammalian cells. However, they have potential to be 
considered as candidates for anti-trypanosomal and anti-leishmanial drug development although more 
studies on toxicity using other cell lines are needed to discriminate whether the toxicity shown by these 
compounds is against tumor or non-tumor cells. The activity is dependent on the length of the alkyl 
linker being compound 19, with a four-carbon alkyl chain, the most performing one. In general, 
hydroxyl groups increase both activity and cytotoxicity and the presence of a double bond in the side 
chain is not decisive for cytotoxicity and anti-protozoal activity. The mechanism of action of these 
compounds needs to be addressed and will be the objective of further studies.  
 
 
4. Experimental section 
4.1. Chemical synthesis 
4.1.1. General remarks 
Microwave reactions were carried out in a CEM Discover microwave reactor in sealed vessels 
(monowave, maximum power 300 W, temperature control by IR sensor, fixed temperature). 1H and 13C 
NMR spectra were recorded on a Varian instrument operating at 500 and 125 MHz, respectively. The 
signals of the deuterated solvent (CDCl3 or CD3OD) were used as reference (CDCl3: δ = 7.27 ppm for 
1H NMR and δ = 77.00 ppm for 13C NMR; CD3OD: δ = 3.31 and 4.87 ppm for 1H NMR and δ = 49.2 
ppm for 13C NMR). Carbon atom types (C, CH, CH2, CH3) were determined by using the DEPT or 
APT pulse sequence. Signal were assigned using two-dimensional heteronuclear correlations (COSY 
and HSQC). High resolution mass spectra were recorded using electrospray ionization mass 
spectrometry (ESI-MS). A QTOF Premier instrument with an orthogonal Z-spray-electrospray 
interface (Waters, Manchester, UK) was used operating in the  
W-mode. The drying and cone gas was nitrogen set to flow rates of 300 and 30 L/h, respectively. 
Methanol sample solutions (ca. 1 × 10−5 M) were directly introduced into the ESI spectrometer at a 
flow rate of 10 µL/min. A capillary voltage of 3.5 kV was used in the positive scan mode, and the cone 
voltage set to Uc = 10 V. For accurate mass measurements, a 2 mg/L standard solution of leucine 
enkephalin was introduced via the lock spray needle at a cone voltage set to 85 V and a flow rate of  
30 μL/min. IR spectra were recorded on a Spectrum RX I FT-IR system (Perkin-Elmer, Waltham, MA, 
USA) in KBr disks. Silica gel 60 (0.063–0.200 mesh, Merck, Whitehouse Station, NJ, USA) was used 
for column chromatography, and precoated silica gel plates (Merck 60 F254 0.2 mm) were used for 
thin layer chromatography (TLC).  
 
4.1.2. General procedure for the synthesis of triclosanalkyl-alcohols 2-8: 
Triclosan, (3.1 mmol, 900 mg), potassium hydroxide (4.0 mmol, 224 mg) and acetonitrile (10 mL), 
were placed into in a 50 mL flat-bottomed flask equipped with a magnetic stirring bar. The mixture was 
stirred and heated to reflux under microwave irradiation for a period of 5 min. Then, ɷ-
bromoalkylalcohols (3.2 mmol) were added and the reaction mixture was refluxed for 30 minutes under 
microwave irradiation (200 W). The crude reaction mixture was evaporated under reduced pressure and 
the residue was purified by column chromatography over silica gel eluting with Hexanes and a mixture 
of Hexanes-Ethyl acetate (9:1 ratio) to obtain the alkyltriclosanalcohols in yields ranging between 
61%–88%. Monitoring of the reaction progress and product purification was carried out by TLC.   
4.1.2.1. 3-(5-chloro-2-(2,4-dichlorophenoxy)phenoxy)propan-1-ol (2). Yield  73%  (2.19 mmol,  759.7 
mg);  clear oil; 1H-NMR (CDCl3, 500 MHz): δ 1.88–1.94 (CH2, m), 3.65 (-CH2OH, t, J = 5.9 Hz), 4.10 
(-CH2O-, t, J = 5.9 Hz), 6.67 (H3, d, J = 8.8 Hz), 6.92-6.94 (H4, H12, m), 7.01 (H6, sapparent), 7.11 (H11, 
dd, J = 8.8, 2.5 Hz), 7.44 (H9, d, J = 2.5 Hz);  13C-NMR (CDCl3, 125 MHz): δ 31.64 (CH2), 59.78 (-
CH2OH), 66.87 (-OCH2-), 114.83 (C6), 118.02 (C3), 121.20 (C12), 121.68 (C4), 124.52 (C5), 127.59 
(C11), 128.04 (C8), 130.21 (C9), 130.50 (C10), 143.08 (C2), 150.64 (C1), 152.21 (C7).  
4.1.2.2. 4-(5-chloro-2-(2,4-dichlorophenoxy)phenoxy)butan-1-ol (3). Yield  61%  (1.83  mmol,  660.8  
mg);  clear oil;  1H-NMR (CDCl3, 500 MHz): δ 1.48–1.56 (CH2, m), 1.72–1.79 (CH2, m), 3.60 (-
CH2OH, t, J = 6.4 Hz), 3.98 (-CH2O-, t, J = 6.2 Hz), 6.66 (H3, d, J = 8.8 Hz), 6.92-6.95 (H4, H12, m), 
6.97 (H6, d, J = 2.1), 7.10 (H11, dd, J = 8.8, 2.5 Hz), 7.44 (H9, d, J = 2.5 Hz);  13C-NMR (CDCl3, 125 
MHz): δ 25.44 (CH2), 29.03 (CH2), 62.39 (-CH2OH), 68.93 (-OCH2-), 114.79 (C6), 117.95 (C3), 121.94 
(C12), 121.16 (C4), 124.46 (C5), 127.57 (C11), 127.86 (C8), 130.13 (C9), 130.65 (C10), 143.07 (C2), 
150.78 (C1), 152.47 (C7).  
4.1.2.3. 5-(5-chloro-2-(2,4-dichlorophenoxy)phenoxy)pentan-1-ol (4). Yield  62%  (1.87  mmol,  702.3  
mg);  clear oil; 1H-NMR (CDCl3, 500 MHz): δ 1.24–1.32 (CH2, m), 1.47–1.55 (CH2, m), 1.62–1.70 
(CH2, m), 3.58 (-CH2OH, t, J = 6.4 Hz), 3.92 (-CH2O-, t, J = 6.2 Hz), 6.63 (H3, d, J = 8.3 Hz), 6.92 (H4, 
dd, J = 8.3, 2.2), 6.96 (H6, d, J = 2.2), 6.98 (H12, d, J = 8.8), 7.08 (H11, dd, J = 8.8, 2.5 Hz), 7.43 (H9, d, 
J = 2.5 Hz); 13C-NMR (CDCl3, 125 MHz): δ 22.02 (CH2), 28.66 (CH2), 32.20 (CH2), 62.66 (-CH2OH), 
68.90 (-OCH2-), 114.69 (C6), 117.65 (C3), 120.90 (C12), 122.23 (C4), 124.24 (C5), 127.48 (C11), 127.62 
(C8), 130.04 (C9), 130.65 (C10), 142.88 (C2), 150.95 (C1), 152.60 (C7).  
4.1.2.4. 7-(5-chloro-2-(2,4-dichlorophenoxy)phenoxy)heptan-1-ol (5). Yield  64%  (1.93  mmol,  780.2  
mg);  clear oil; 1H-NMR (CDCl3, 500 MHz): δ 1.17–1.25 (CH2, m), 1.25–1.34 (CH2, m), 1.49–1.58 
(CH2, m), 1.59–1.67 (CH2, m), 3.64 (-CH2OH, t, J = 6.5 Hz), 3.91 (-CH2O-, t, J = 6.2 Hz), 6.63 (H3, d, 
J = 8.5 Hz), 6.92 (H4, dd, J = 8.5, 2.4), 6.96 (H6, d, J = 2.4), 6.98 (H12, d, J = 8.8), 7.08 (H11, dd, J = 8.8, 
2.6 Hz), 7.43 (H9, d, J = 2.6 Hz); 13C-NMR (CDCl3, 125 MHz): δ 25.58 (CH2), 25.67 (CH2), 28.84 
(CH2), 28.95 (CH2), 32.65 (CH2), 62.97 (-CH2OH), 69.97 (-OCH2-), 114.67 (C6), 117.57 (C3), 120.82 
(C12), 122.30 (C4), 124.22 (C5), 127.45 (C11), 127.56 (C8), 130.05 (C9), 130.67 (C10), 142.85 (C2), 
151.04 (C1), 152.68 (C7).  
4.1.2.5. 8-(5-chloro-2-(2,4-dichlorophenoxy)phenoxy)octan-1-ol (6). Yield  65%  (2.02 mmol,  841  
mg);  pale yellow oil; 1H-NMR (CDCl3, 500 MHz): δ 1.09–1.42 (4CH2, m), 1.50–1.75 (2CH2, m), 3.67 
(-CH2OH, t, J = 6.5 Hz), 3.93 (-CH2O-, t, J = 6.2 Hz), 6.65 (H3, d, J = 8.8 Hz), 6.90-6.99 (H4, H6, m), 
7.02 (H12, d, J = 8.8), 7.11 (H11, dd, J = 8.8, 2.4 Hz), 7.45 (H9, d, J = 2.4 Hz); 13C-NMR (CDCl3, 125 
MHz): δ 25.68 (2CH2), 28.92 (CH2), 29.21 (CH2), 29.32 (CH2), 32.77 (CH2), 63.00 (-CH2OH), 68.98 (-
OCH2-), 114.61 (C6), 117.61 (C3), 120.82 (C12), 122.37 (C4), 124.21 (C5), 127.52 (C11), 127.60 (C8), 
130.08 (C9), 130.72 (C10), 142.82 (C2), 151.11 (C1), 152.72 (C7).  
4.1.2.6. 9-(5-chloro-2-(2,4-dichlorophenoxy)phenoxy)nonan-1-ol (7). Yield  77%  (2.31 mmol,  998.4  
mg);  clear oil;  1H-NMR (CDCl3, 500 MHz): δ 1.14–1.26 (4CH2, m), 1.26–1.32 (CH2, m), 1.32–1.40 
(CH2, m), 1.53–1.66 (CH2, m), 3.65 (-CH2OH, t, J = 6.8 Hz), 3.91 (-CH2O-, t, J = 6.4 Hz), 6.63 (H3, d, 
J = 8.8 Hz), 6.92 (H4, dd, J = 8.8, 2.3), 6.96 (H6, d, J = 2.3), 6.98 (H12, d, J = 8.8), 7.08 (H11, dd, J = 8.8, 
2.5 Hz), 7.43 (H9, d, J = 2.5 Hz); 13C-NMR (CDCl3, 125 MHz): δ 25.67 (CH2), 25.69 (CH2), 28.89 
(CH2), 29.11 (CH2), 29.28 (CH2), 29.41 (CH2), 32.77 (CH2), 63.04 (-CH2OH), 69.04 (-OCH2-), 114.68 
(C6), 117.60 (C3), 120.80 (C12), 122.27 (C4), 124.21 (C5), 127.44 (C11), 127.60 (C8), 130.05 (C9), 
130.61 (C10), 142.87 (C2), 151.09 (C1), 152.67 (C7).  
4.1.2.7. 12-(5-chloro-2-(2,4-dichlorophenoxy)phenoxy)dodecan-1-ol (8). Yield  88%  (2.65 mmol,  
1255  mg);  clear oil;  1H-NMR (CDCl3, 500 MHz): δ 1.15–1.26 (5CH2, m), 1.26–1.41 (3CH2, m), 
1.54–1.65 (2CH2, m), 3.65 (-CH2OH, t, J = 6.5 Hz), 3.90 (-CH2O-, t, J = 6.3 Hz), 6.63 (H3, d, J = 8.6 
Hz), 6.92 (H4, dd, J = 8.6, 2.0), 6.96 (H6, d, J = 2.0), 6.98 (d, J = 8.8, H12), 7.08 (H11, dd, J = 8.8, 2.5 
Hz), 7.42 (H9, d, J = 2.5 Hz); 13C-NMR (CDCl3, 125 MHz): δ 25.69 (CH2), 25.72 (CH2), 28.90 (CH2), 
29.19 (CH2), 29.41 (CH2), 29.46 (CH2), 29.50 (CH2), 29.53 (CH2), 29.56 (CH2), 32.81 (CH2), 63.07 (-
CH2OH), 69.07 (-OCH2-), 114.68 (C6), 117.62 (C3), 120.77 (C12), 122.25 (C4), 124.26 (C5), 127.44 
(C11), 127.61 (C8), 130.05 (C9), 130.63 (C10), 142.95 (C2), 151.10 (C1), 152.66 (C7).  
4.1.3. General procedure for the synthesis of protected esters 11-17:  
Caffeic acid (10 g, 55.51 mmol), tert-butyldimethylsilyl chloride (66.61 mmol, 10 g) and imidazole 
(111.02 mmol, 7.6 g) were  placed into a 50 mL sealed tube. The mixture was heated under microwave 
irradiation (50 W) for a period of 10 min Then, the reaction mixture was poured into water and 
extracted with ethyl acetate. The combined organic phases were dried over anhydrous MgSO4 and the 
solvent was evaporated under reduced pressure. The crude products were purified by column 
chromatography over silica gel eluting with Hexanes and a mixture of Hexanes-Ethyl  acetate (8:2 
ratio) affording silyl protected caffeic acid 10 in 52% yield (28.87 mmol, 11.8g). Alkyltriclosan 
alcohols 2-8  (0.7 mmol) were dissolved in dry CH2Cl2 (20 mL) and treated sequentially with silyl 
protected caffeic acid 10 (0.73 mmol, 300mg), DMAP (1.2 mmol) and EDC (1.2 mmol). The reaction 
mixture was stirred for 24 h and filtered. The resulting solution was concentrated under reduced 
pressure and the residue was purified by column chromatography over silica gel eluting with Hexanes 
and a mixture of  Hexanes-Ethyl  acetate  (9:1 ratio) affording compounds 11-17 in yields ranging 
between 41%–60%. 
4.1.3.1. 3-(5-chloro-2-(2,4-dichlorophenoxy)phenoxy)propyl (E)-3-(3,4-bis((tert-
butyldimethylsilyl)oxy)phenyl)prop-2-enoate (11). Yield  41%  (0.284  mmol,  212  mg);  pale yellow 
oil; 1H-NMR (CDCl3, 500 MHz): δ 0.25 (CH3-Si), 0.26 (CH3-Si), 1.03 (CH3-C-Si), 1.04 (CH3-C-Si), 
2.00-2.15 (CH2, m), 4.11 (-CH2O-, t, J = 6.1 Hz), 4.20 (-CH2O-, t, J = 6.2 Hz), 6.23 (H2, d, J = 16.0 
Hz), 6.71 (H12, d, J = 8.8 Hz), 6.86 (H8, d, J = 8.8 Hz), 6.96-70.1 (H13, H15, H21, m), 7.02-7.08 (H5, H9, 
m), 7.13 (H20, dd, J = 8.8, 2.5 Hz), 7.47 (H18, d, J = 2.5 Hz), 7.59 (H3, d, J = 16.0 Hz); 13C-NMR 
(CDCl3, 125 MHz): δ -4.02 (CH3-Si), -4.06 (CH3-Si), 18.47 (-C-Si), 18.53 (-C-Si), 25.62 (CH2), 25.83 
(CH2), 25.90 (CH3-C-Si), 25.93 (CH3-C-Si), 28.58 (CH2), 60.63 (-OCH2-), 65.64 (-OCH2-), 114.95 
(C8), 115.37 (C5), 118.01 (C15), 120.49 (C2), 121.17 (C12), 121.31 (C21), 122.06 (C8), 122.33 (C9), 
124.48 (C14), 127.67 (C17), 127.94 (C20), 128.05 (C4), 130.24 (C18), 130.56 (C19), 143.22 (C11), 144.97 
(C3), 147.20 (C6), 149.54 (C10), 151.71 (C16), 152.39 (C7), 167.12 (C = O). 
4.1.3.2. 4-(5-chloro-2-(2,4-dichlorophenoxy)phenoxy)butyl (E)-3-(3,4-bis((tert-
butyldimethylsilyl)oxy)phenyl)prop-2-enoate (12). Yield  43%  (0.304 mmol,  231 mg);  pale yellow 
oil; 1H-NMR (CDCl3, 500 MHz): δ 0.93 (CH3-Si), 0.95 (CH3-C-Si), 1.56-1.70 (CH2, m), 1.71-1.87 
(CH2, m), 4.00 (-CH2O-, t, J = 6.1 Hz), 4.14 (-CH2O-, t, J = 6.0 Hz), 6.23 (H2, d, J = 16.0 Hz), 6.67 
(H12, d, J = 8.6 Hz), 6.79-6.89 (H8, H13, H21, m), 6.92-7.06 (H5, H9, H15, m), 7.08-7.16 (H20, m), 7.46 
(H18, d, J = 2.4 Hz), 7.59 (H3, d, J = 16.0 Hz); 13C-NMR (CDCl3, 125 MHz): δ 3.55 (CH3-Si), 4.03 
(CH3-Si), 18.02 (-C-Si), 18.47 (-C-Si), 25.07 (CH2), 25.63 (CH2), 25.68 (CH3-C-Si), 25.92 (CH3-C-Si), 
45.48 (2CH2), 63.54 (-OCH2-), 68.39 (-OCH2-), 114.17 (C8), 114.36 (C5), 114.73 (C15), 115.75 (C2), 
117.75 (C12), 121.07 (C21), 121.80 (C8), 122.28 (C9), 124.33 (C14), 126.22 (C17), 127.59 (C20), 127.81 
(C4), 130.16 (C18), 130.69 (C19), 142.97 (C11), 145.60 (C3), 146.03 (C6), 148.95 (C10), 150.86 (C16), 
152.61 (C7), 167.69 (C = O). 
4.1.3.3. 5-(5-chloro-2-(2,4-dichlorophenoxy)phenoxy)pentyl (E)-3-(3,4-bis((tert-
butyldimethylsilyl)oxy)phenyl)prop-2-enoate (13). Yield  59%  (0.41 mmol,  317 mg);  pale yellow oil; 
1H-NMR (CDCl3, 500 MHz): δ 0.23 (CH3-Si), 1.00 (CH3-C-Si), 1.01 (CH3-C-Si), 1.52–1.61 (CH2, m), 
1.62–1.74 (2CH2, m), 3.95 (-CH2O-, t, J = 6.3 Hz), 4.14 (-CH2O-, t, J = 6.8 Hz), 6.23 (H2, d, J = 16.0 
Hz), 6.64 (H12, d, J = 8.8 Hz), 6.83 (H8, d, J = 8.8 Hz), 6.93 (H13, dd, J = 8.8, 2.2), 6.96 (H15, d, J = 
2.2), 6.98 (H21, d, J = 8.7), 7.03 (H5, sapparent), 7.06 (H9, dd, J = 8.8, 2.5 Hz), 7.09 (H20, dd, J = 8.7, 2.5 
Hz), 7.41 (H18, d, J = 2.5 Hz), 7.57 (H3, d, J = 16.0 Hz); 13C-NMR (CDCl3, 125 MHz): δ -4.06 (CH3-
Si), -4.10 (CH3-Si), 18.43 (-C-Si), 18.48 (-C-Si), 25.87 (CH3-C-Si), 25.89 (CH3-C-Si), 22.18 (CH2), 
28.40 (2CH2), 64.10 (-OCH2-), 68.76 (-OCH2-), 114.67 (C8), 114.79 (C5), 117.60 (C15), 117.74 (C2), 
120.92 (C12), 121.01 (C21), 122.17 (C8), 122.28 (C9), 124.23 (C14), 127.48 (C17), 127.57 (C20), 127.76 
(C4), 130.01 (C18), 130.74 (C19), 142.98 (C11), 144.60 (C3), 146.26 (C6), 150.94 (C10), 152.60 (C16), 
152.68 (C7), 167.25 (C = O). 
4.1.3.4. 7-(5-chloro-2-(2,4-dichlorophenoxy)phenoxy)heptyl (E)-3-(3,4-bis((tert-
butyldimethylsilyl)oxy)phenyl)prop-2-enoate (14). Yield  60%  (0.420 mmol,  337 mg);  pale yellow 
oil; 1H-NMR (CDCl3, 500 MHz): δ 0.14 (CH3-Si), 0.91 (CH3-C-Si), 0.92 (CH3-C-Si), 1.09–1.30 
(3CH2, m), 1.50–1.63 (2CH2, m), 3.82 (-CH2O-, t, J = 6.2 Hz), 4.10 (-CH2O-, t, J = 6.8 Hz), 6.16 (H2, 
d, J = 16.0 Hz), 6.54 (H12, d, J = 8.8 Hz), 6.74 (H8, d, J = 8.9 Hz), 6.83 (H13, dd, J = 8.8, 2.4), 6.87 
(H15, d, J = 2.4), 6.90 (H21, d, J = 8.6), 6.92-6.95 (H5, H9, m), 6.99 (H20, dd, J = 8.6, 2.6 Hz), 7.34 (H18, 
d, J = 2.6 Hz), 7.49 (H3, d, J = 16.0 Hz); 13C-NMR (CDCl3, 125 MHz): δ -4.07 (CH3-Si), -4.11 (CH3-
Si), 18.42 (-C-Si), 18.47 (-C-Si), 25.62 (CH2), 25.83 (CH2), 25.86 (CH3-C-Si), 25.89 (CH3-C-Si), 28.66 
(CH2), 28.85 (CH2), 28.86 (CH2), 64.42 (-OCH2-), 68.96 (-OCH2-), 114.69 (C8), 115.86 (C5), 117.57 
(C15), 120.37 (C2), 120.83 (C12), 121.11 (C21), 122.19 (C8), 122.30 (C9), 124.24 (C14), 127.44 (C17), 
127.62 (C20), 128.07 (C4), 130.06 (C18), 130.67 (C19), 142.88 (C11), 144.50 (C3), 147.15 (C6), 149.35 
(C10), 151.05 (C16), 152.66 (C7), 167.34 (C = O). 
4.1.3.5. 8-(5-chloro-2-(2,4-dichlorophenoxy)phenoxy)octyl (E)-3-(3,4-bis((tert-
butyldimethylsilyl)oxy)phenyl)prop-2-enoate (15). Yield  54%  (0.378  mmol,  306 mg);  pale yellow 
oil; 1H-NMR (CDCl3, 500 MHz): δ 0.25 (CH3-Si), 0.26 (CH3-Si),  1.03 (CH3-C-Si), 1.04 (CH3-C-Si), 
1.14-1.45 (2CH2, m), 1.56–1.69 (4CH2, m), 3.94 (-CH2O-, t, J = 6.4 Hz), 4.23 (-CH2O-, t, J = 6.5 Hz), 
6.28 (H2, d, J = 16.1 Hz), 6.66 (H12, d, J = 8.8 Hz), 6.86 (H8, d, J = 8.7 Hz), 6.96 (H13, dd, J = 8.8, 2.0), 
6.98-7.02 (H21, H15, m), 7.03-7.08 (H5, H9, m), 7.11 (H20, dd, J = 8.7, 2.0 Hz), 7.47 (H18, d, J = 2.0 Hz), 
7.61 (H3, d, J = 16.1 Hz); 13C-NMR (CDCl3, 125 MHz): δ -4.03 (CH3-Si), -4.07 (CH3-Si), 18.47 (-C-
Si), 18.53 (-C-Si), 25.69 (CH2), 25.91 (CH3-C-Si), 25.93 (CH3-C-Si), 28.62 (CH2), 28.79 (CH2), 28.91 
(CH2),  29.14 (CH2),  29.17 (CH2), 29.20 (CH2), 64.50 (-OCH2-), 68.94 (-OCH2-), 114.62 (C8), 117.59 
(C5), 120.44 (C15), 120.83 (C2), 121.16 (C12), 122.27 (C21), 122.33 (C8), 122.36 (C9), 125.81 (C14), 
127.51 (C17), 127.66 (C20), 128.08 (C4), 130.11 (C18), 130.72 (C19), 142.93 (C11), 144.59 (C3), 148.34 
(C6), 149.44 (C10), 151.12 (C16), 152.62 (C7), 167.46 (C = O). 
4.1.3.6. 9-(5-chloro-2-(2,4-dichlorophenoxy)phenoxy)nonyl (E)-3-(3,4-bis((tert-
butyldimethylsilyl)oxy)phenyl)prop-2-enoate (16). Yield  49%  (0.344 mmol,  286  mg);  pale yellow 
oil; 1H-NMR (CDCl3, 500 MHz): δ 0.22 (CH3-Si), 0.23 (CH3-Si),  1.00 (CH3-C-Si), 1.01 (CH3-C-Si), 
1.15–1.46 (5CH2, m), 1.56–1.66 (CH2, m), 1.67–1.76 (CH2, m), 3.91 (-CH2O-, t, J = 6.2 Hz), 4.20 (-
CH2O-, t, J = 6.8 Hz), 6.25 (H2, d, J = 16.0 Hz), 6.63 (H12, d, J = 8.8 Hz), 6.83 (H8, d, J = 8.8 Hz), 6.83 
(H13, dd, J = 8.8, 2.1), 6.96 (H15, d, J = 2.1), 6.98 (H21, d, J = 8.9), 7.01-7.04 (H5, H9, m), 7.08 (H20, dd, 
J = 8.9, 2.4 Hz), 7.43 (H18, d, J = 2.4 Hz), 7.57 (H3, d, J = 16.0 Hz); 13C-NMR (CDCl3, 125 MHz): δ -
4.06 (CH3-Si), -4.10 (CH3-Si), 18.43 (-C-Si), 18.48 (-C-Si), 25.70 (CH2), 25.87 (CH3-C-Si), 25.90 
(CH3-C-Si), 25.95 (CH2), 28.77 (CH2), 28.91 (CH2), 29.13 (CH2),  29.18 (CH2),  29.37 (CH2), 29.68 
(CH2), 64.53 (-OCH2-), 68.04 (-OCH2-), 114.70 (C8), 115.90 (C5), 117.60 (C15), 120.38 (C2), 120.80 
(C12), 121.11 (C21), 122.19 (C8), 122.30 (C9), 124.23 (C14), 127.44 (C17), 127.61 (C20), 128.09 (C4), 
130.06 (C18), 130.67 (C19), 142.92 (C11), 144.48 (C3), 147.16 (C6), 149.34 (C10), 151.11 (C16), 152.70 
(C7), 167.37 (C = O). 
4.1.3.7. 12-(5-chloro-2-(2,4-dichlorophenoxy)phenoxy)dodecyl (E)-3-(3,4-bis((tert-
butyldimethylsilyl)oxy)phenyl)prop-2-enoate (17). Yield  52%  (0.366 mmol,  319 mg);  pale yellow 
oil; 1H-NMR (CDCl3, 500 MHz): δ 0.22 (CH3-Si), 0.23 (CH3-Si),  1.00 (CH3-C-Si), 1.01 (CH3-C-Si), 
1.14–1.47 (8CH2, m), 1.57–1.66 (CH2, m), 1.67–1.75 (CH2, m), 3.91 (-CH2O-, t, J = 6.3 Hz), 4.20 (-
CH2O-, t, J = 6.8 Hz), 6.24 (H2, d, J = 16.0 Hz), 6.63 (H12, d, J = 8.8 Hz), 6.83 (H8, d, J = 8.8 Hz), 6.92 
(H13, dd, J = 8.8, 2.2), 6.96 (H15, d, J = 2.2), 6.98 (H21, d, J = 8.8), 7.01-7.04 (H5, H9, m), 7.08 (H20, dd, 
J = 8.8, 2.5 Hz), 7.42 (H18, d, J = 2.5 Hz), 7.57 (H3, d, J = 16.0 Hz); 13C-NMR (CDCl3, 125 MHz): δ -
4.06 (CH3-Si), -4.10 (CH3-Si), 18.43 (-C-Si), 18.48 (-C-Si), 25.70 (CH2), 25.87 (CH3-C-Si), 25.90 
(CH3-C-Si), 25.98 (CH2), 28.79 (CH2), 28.92 (CH2), 29.20 (CH2),  29.30 (CH2),  29.47 (CH2),  29.51 
(CH2),  29.55 (CH2), 29.68 (CH2), 64.57 (-OCH2-), 68.08 (-OCH2-), 114.70 (C8), 115.90 (C5), 117.61 
(C15), 120.38 (C2), 120.78 (C12), 121.11 (C21), 122.18 (C8), 122.27 (C9), 124.24 (C14), 127.44 (C17), 
127.61 (C20), 128.10 (C4), 130.06 (C18), 130.65 (C19), 142.88 (C11), 144.46 (C3), 147.19 (C6), 149.34 
(C10), 151.12 (C16), 152.67 (C7), 167.38 (C = O). 
4.1.4. General procedure for the synthesis of esters 18-24:  
Compounds 11-17 (0.25 mmol) were dissolved in dioxane (8 mL) and treated with benzoic acid (BA) 
(0.03 mmol) and TBAF (1 mmol). The mixture was then heated at reflux for 12 h, cooled, and 
neutralized by addition of solid NaHCO3. After filtration, the solution was evaporated in vacuo, and the 
residue was subjected to column chromatography on silica gel (EtOAc-MeOH, 1:1) affording  
compounds 18-24 in yields between 50-98%. 
4.1.4.1. 3-(5-chloro-2-(2,4-dichlorophenoxy)phenoxy)propyl (E)-3-(3,4-dihydroxyphenyl) prop-2-
enoate (18). Yield  73%  (0.183 mmol,  93 mg);  pale yellow oil; IR (KBr, cm-1): vmax  3483 (OH), 
2927 (C-H), 1685 (C=O), 1600 (C=C), 1477 (C=CAr), 1269 (C-O-C), 1184 ((C=O)-O), 800 (C-HAr), 
700 (C-Cl). 1H-NMR (CD3OD-CDCl3, 300 MHz): δ 1.87–2.06 (CH2, m), 4.06 (-CH2O-, t, J = 6.5 Hz), 
6.21 (H2, d, J = 16.0 Hz), 6.06 (H12, d, J = 8.9 Hz), 6.78 (H8, d, J = 8.1 Hz), 6.92 (H13, dd, J = 8.8, 1.7 
Hz), 6.95-7.05 (H15, H21, m), 7.10-7.18 (H5, H9, H20, m), 7.46 (H18, d, J = 2.5 Hz), 7.50 (H3, d, J = 16.0 
Hz); 13C-NMR (CD3OD-CDCl3, 75 MHz): δ 18.13 (CH2), 28.18 (CH2), 65.34 (-OCH2-), 61.17 (-
OCH2-), 113.56 (C15), 113.78 (C5), 114.67 (C8), 115.08 (C2), 117.43 (C12), 120.95 (C21), 121.60 (C13), 
122.17 (C9), 123.75 (C14), 126.30 (C17), 127.48 (C20), 127.60 (C4), 129.68 (C19), 130.56 (C18), 142.85 
(C11), 145.38 (C6), 145.54 (C3), 148.17 (C7), 150.89 (C10), 152.63 (C16), 167.68 (C = O). EIMS: m/z 
531.0145  [M + Na]+, Calcd. for C24H19Cl3O6 : 531.0129. 
4.1.4.2. 4-(5-chloro-2-(2,4-dichlorophenoxy)phenoxy)butyl (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate 
(19). Yield  62%  (0.155 mmol,  81 mg);  pale yellow solid; m.p. 154–156 °C; IR (KBr, cm-1): vmax  
3483 (OH), 2924 (C-H),  1685 (C=O), 1600 (C=C), 1473 (C=CAr),  1274 (C-O-C), 1190 ((C=O)-O), 
804 (C-HAr),  700 (C-Cl). 1H-NMR (DMSO-D6, 500 MHz): δ 1.40–1.50 (CH2, m), 1.56–1.64 (CH2, m), 
4.01 (-CH2O-, t, J = 6.1 Hz), 6.23 (H2, d, J = 16.0 Hz), 6.73 (H12, d, J = 8.8 Hz), 6.76 (H8, d, J = 8.0 
Hz), 6.97 (H13, dd, J = 8.1, 2.0), 7.00-7.09 (H12, H15, m), 7.15 (H20, dd, J = 8.6, 2.4), 7.24-7.30 (H5, H9, 
m), 7.45 (H3, d, J = 16.0 Hz), 7.64 (H18, d, J = 2.4 Hz); 13C-NMR (DMSO-D6, 125 MHz): δ 24.50 
(CH2), 25.00 (CH2), 64.07 (-OCH2-), 68.09 (-OCH2-), 114.73 (C15), 114.80 (C5), 115.68 (C8), 117.90 
(C2), 120.82 (C12), 121.26 (C21), 122.63 (C13), 123.02 (C9), 125.46 (C14), 126.65 (C17), 128.16 (C20), 
129.50 (C4), 129.57 (C19), 129.85 (C18), 142.16 (C11), 144.92 (C6), 145.53 (C3), 148.34 (C7), 150.61 
(C10), 152.22 (C16), 166.38 (C = O). EIMS: m/z 545.0301 [M + Na]+, Calcd. for C25H21Cl3O6 : 
545.0287. 
4.1.4.3. 5-(5-chloro-2-(2,4-dichlorophenoxy)phenoxy)pentyl (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate 
(20). Yield  50%  (0.125 mmol,  67 mg);  pale yellow solid; m.p. 126-128°C; IR (KBr, cm-1): vmax  
3471 (OH), 2933 (C-H),  1689 (C=O), 1602 (C=C), 1477 (C=CAr), 1273(C-O-C), 1186 ((C=O)-O), 812 
(C-HAr),  700 (C-Cl). 1H-NMR (DMSO-D6, 500 MHz): δ 1.13–1.22 (CH2, m), 1.47–1.58 (2CH2, m), 
3.97 (-CH2O-, t, J = 6.0 Hz), 4.01 (-CH2O-, t, J = 6.6 Hz), 6.23 (H2, d, J = 16.0 Hz), 6.73 (H12, d, J = 
8.7 Hz), 6.76 (H8, d, J = 8.2 Hz), 6.98 (H13, dd, J = 8.7, 2.0), 7.02-7.07 (H9, H15, m), 7.16 (H21, d, J = 
8.8 Hz), 7.26 (H5, d, J = 2.3 Hz), 7.28 (H20, dd, J = 8.8, 2.6), 7.46 (H3, d, J = 16.0 Hz), 7.65 (H18, d, J = 
2.6 Hz); 13C-NMR (DMSO-D6, 125 MHz): δ 26.96 (CH2), 33.04 (CH2), 33.22 (CH2), 68.73 (-OCH2-), 
73.64 (-OCH2-), 119.10 (C15), 119.17 (C5), 120.00 (C8), 120.92 (C2), 123.11 (C12), 126.00 (C21), 126.50 
(C13), 127.90 (C9), 128.23 (C14), 130.67 (C17), 131.83 (C20), 133.43 (C4), 134.78 (C19), 135.11 (C18), 
147.36 (C11), 150.10 (C6), 150.78 (C3), 153.62 (C7), 155.95 (C10), 157.51 (C16), 171.7 (C = O). EIMS: 
m/z 559.0458  [M + Na]+, Calcd. for C26H23Cl3O6 : 559,0466. 
4.1.4.4. 7-(5-chloro-2-(2,4-dichlorophenoxy)phenoxy)heptyl (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate 
(21). Yield  92%  (0.230 mmol,  130 mg);  pale yellow oil; IR (KBr, cm-1): vmax  3387 (OH), 2935 (C-
H),  1689 (C=O), 1598 (C=C), 1496 (C=CAr), 1269 (C-O-C), 1190 ((C=O)-O), 800 (C-HAr),  704 (C-
Cl). 1H-NMR (CD3OD, 300 MHz): δ 1.17–1.38 (3CH2, m), 1.47–1.72 (2CH2, m), 3.89 (-CH2O-, t, J = 
6.0 Hz), 4.15 (-CH2O-, t, J = 6.4 Hz), 6.26 (H2, d, J = 16.0 Hz), 6.61 (H12, d, J = 8.8 Hz), 6.78 (H8, d, J 
= 8.2 Hz), 6.90-7.00 (H9, H15, m), 7.01-7.10 (H5, H13, H21, m), 7.14 (H20, dd, J = 8.8, 2.5), 7.46 (H18, d, 
J = 2.5 Hz), 7.54 (H3, d, J = 16.0 Hz); 13C-NMR (CD3OD, 75 MHz): δ 25.43 (CH2), 25.63 (CH2), 28.35 
(CH2), 28.59 (CH2), 28.65 (CH2), 64.17 (-OCH2-), 68.45 (-OCH2-), 113.71 (C15), 113.84 (C5), 114.23 
(C8), 115.10 (C2), 116.91 (C12), 120.51 (C21), 121.55 (C13), 122.56 (C9), 123.47 (C14), 126.27 (C17), 
127.01 (C20), 127.45 (C4), 129.56 (C19), 130.78 (C18), 142.35 (C11), 145.40 (C6), 145.44 (C3), 148.21 
(C7), 151.25 (C10), 153.00 (C16), 168.62 (C = O). EIMS: m/z 587.0771  [M + Na]+, Calcd. for 
C28H27Cl3O6: 587.0772. 
4.1.4.5. 8-(5-chloro-2-(2,4-dichlorophenoxy)phenoxy)octyl (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate 
(22). Yield  92%  (0.230 mmol,  133 mg);  pale yellow oil; IR (KBr, cm-1): vmax  3421 (OH), 2926 (C-
H),  1683 (C=O), 1600 (C=C), 1469 (C=CAr), 1267 (C-O-C), 1188 ((C=O)-O), 806 (C-HAr),  702 (C-
Cl). 1H-NMR (CD3OD-CDCl3, 300 MHz): δ 1.11–1.49 (4CH2, m), 1.69–1.81 (CH2, m), 1.58-1.69 
(CH2, m), 3.94 (-CH2O-, t, J = 6.2 Hz), 4.23 (-CH2O-, t, J = 6.7 Hz), 6.30 (H2, dd, J = 15.8 Hz), 6.66 
(H12, d, J = 8.8 Hz), 6.91 (H21, d, J = 8.1 Hz), 6.96  (H13, dd, J = 8.8, 2.4 Hz), 6.98-7.01 (H15, H21, m), 
7.02-7.06 (H5, H9, m), 7.11 (H20, dd, J = 8.8, 2.5 Hz), 7.46 (H18, d, J = 2.5 Hz), 7.62 (H3, d, J = 15.8 
Hz); 13C-NMR (CD3OD-CDCl3, 75 MHz): δ 25.68 (CH2), 25.91 (CH2), 28.72 (CH2), 28.91 (CH2), 
29.13 (CH2), 29.17 (CH2), 64.80 (-OCH2-), 68.99 (-OCH2-), 114.36 (C15), 114.63 (C5), 115.46 (C8), 
115.59 (C2), 117.65 (C12), 120.85 (C13), 122.33 (C9), 124.24 (C14), 127.46 (C17), 127.52 (C20), 127.66 
(C4), 130.10 (C19), 130.71 (C18), 142.84 (C11), 143.97 (C6), 144.93 (C3), 146.50 (C7), 151.07 (C10), 
152.68 (C16), 167.95 (C = O). EIMS: m/z 601.0933   [M + Na]+, Calcd. for C29H29Cl3O6: 601,0904. 
4.1.4.6. 9-(5-chloro-2-(2,4-dichlorophenoxy)phenoxy)nonyl (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate 
(23). Yield  81%  (0.203 mmol,  126 mg);  pale yellow oil; IR (KBr, cm-1): vmax  3406 (OH), 2929 (C-
H),  1689 (C=O), 1606 (C=C), 1477 (C=CAr), 1269 (C-O-C), 1190 ((C=O)-O), 810 (C-HAr),  744 (C-
Cl). 1H-NMR (CD3OD-CDCl3, 300 MHz): δ 1.06–1.45 (5CH2, m), 1.47–1.61 (CH2, m), 1.62–1.75 
(CH2, m), 3.88 (-CH2O-, t, J = 6.0 Hz), 4.16 (-CH2O-, t, J = 6.6 Hz), 6.24 (H2, d, J = 16.0 Hz), 6.60 
(H12, d, J = 8.9 Hz), 6.78 (H8, d, J = 8.9 Hz), 6.88-6.97 (H13, H15, H21, m), 6.99-7.06 (H5, H9, m), 7.10 
(H20, dd, J = 8.9, 2.4 Hz), 7.42 (H18, d, J = 2.4 Hz), 7.53 (H3, d, J = 16.0 Hz); 13C-NMR (CD3OD-
CDCl3, 75 MHz): δ 25.56 (CH2), 25.77 (CH2), 28.51 (CH2), 28.76 (CH2), 28.94 (CH2), 29.20 (CH2), 
64.40 (-OCH2-), 68.64 (-OCH2-), 113.87 (C15), 114.00 (C5), 114.35 (C8), 115.20 (C2), 117.07 (C12), 
120.60 (C21), 121.68 (C13), 122.48 (C9), 123.67 (C14), 126.35 (C17), 127.19 (C20), 127.41 (C4), 129.69 
(C19), 130.80 (C18), 142.45 (C11), 145.31 (C6), 145.52 (C3), 148.05 (C7), 151.18 (C10), 152.88 (C16), 
168.24 (C = O). EIMS: m/z 615.1084  [M + Na]+, Calcd. for C30H31Cl3O6: 615.1080. 
4.1.4.7. 12-(5-chloro-2-(2,4-dichlorophenoxy)phenoxy)dodecyl (E)-3-(3,4-dihydroxyphenyl)prop-2-
enoate (24). Yield  80%  (0.20 mmol,  127 mg);  pale yellow solid; m.p. 78-80°C; IR (KBr, cm-1): vmax  
3483 (OH), 2924 (C-H),  1689 (C=O), 1598 (C=C), 1463 (C=CAr), 1271 (C-O-C), 1174 ((C=O)-O), 
804 (C-HAr), 700 (C-Cl). 1H-NMR (CD3OD, 300 MHz): δ 1.13–1.48 (8CH2, m), 1.55–1.68 (CH2, m), 
1.69–1.82 (CH2, m), 3.93 (-CH2O-, t, J = 6.0 Hz), 4.23 (-CH2O-, t, J = 6.4 Hz), 6.26 (H2, d, J = 16.0 
Hz), 6.66 (H12, d, J = 8.8 Hz), 6.88 (H8, d, J = 8.0 Hz), 7.07-7.17 (H9, H15, m), 6.92-7.05 (H5, H13, H21, 
m), 7.11 (H20, dd, J = 8.6, 2.4), 7.45 (H18, d, J = 2.2 Hz), 7.58 (H3, d, J = 16.0 Hz); 13C-NMR (CD3OD, 
75 MHz): δ 25.75 (CH2), 26.01 (CH2), 28.74 (CH2), 28.93 (CH2), 29.26 (CH2), 29.33 (CH2), 29.55 
(4CH2), 64.90 (-OCH2-), 69.10 (-OCH2-), 114.41 (C15), 114.63 (C5), 115.32 (C8), 115.50 (C2), 117.70 
(C12), 120.80 (C21), 122.30 (C13), 124.26 (C9), 127.29 (C14), 127.52 (C17), 127.66 (C20), 130.10 (C4), 
130.70 (C19), 134.30 (C18), 139.42 (C11), 142.87 (C6), 144.18 (C3), 145.10 (C7), 151.09 (C10), 152.67 
(C16), 168.15 (C = O). EIMS: m/z 657.1553 [M + Na]+, Calcd. for C33H37Cl3O6: 657.1561. 
4.1.5. General procedure for the synthesis of esters (26-29) 
3,4-dimethoxy cinnamic acid 25 (0.96 mmol, 200 mg) and thionyl chloride (5 mL) were placed in a 50 
ml 3-neck round-bottom flask equipped with a magnetic stirring bar. The mixture was heated to reflux 
for 4h. The reaction mixture was then concentrated under reduced pressure and the residue was added 
to a solution of alcohols 2-8 (0.9 mmol) in dichloromethane. The resulting mixture was stirred for 4h, 
transferred to a separation funnel and then 20 mL of an aqueous solution of potassium carbonate was 
added. The organic layer was washed with water, separated, dried on anhydrous sodium sulfate, filtered 
and concentrated under reduced pressure. The residue was chromatographed over silica gel (Hexanes–
Ethyl acetate, different ratios) to obtain the esters 26-29 in yields between 40-60%. 
4.1.5.1. 3-(5-chloro-2-(2,4-dichlorophenoxy)phenoxy)propyl (E)-3-(3,4-dimethoxyphenyl) prop-2-
enoate (26). Yield  46%  (0.41 mmol,  221 mg);  white solid; m.p. 112–114 °C; IR (KBr, cm-1): vmax  
2949 (C-H),  1705 (C=O), 1627 (C=C), 1510 (C=CAr), 1269 (C-O-C), 1172 ((C=O)-O), 798 (C-HAr), 
705 (C-Cl). 1H-NMR (CDCl3, 300 MHz): δ 2.01-2.12 (CH2, m), 3.93 (2OCH3), 4.09 (-CH2O-, t, J = 6.1 
Hz), 4.18 (-CH2O-, t, J = 6.0 Hz), 6.30 (H2, d, J = 16.0 Hz), 6.67 (H12, d, J = 8.7 Hz), 6.88 (H8, d, J = 
8.4 Hz), 6.95 (H15, sapparent), 7.04-7.15 (H5, H9, H13, H20, H21, m), 7.43 (H18, d, J = 2.4 Hz), 7.62 (H3, d, J 
= 16.0 Hz); 13C-NMR (CDCl3, 75 MHz): δ 28.56 (CH2), 55.88 (OCH3), 55.96 (OCH3), 60.64 (-OCH2-
), 68.71 (-OCH2-), 109.60 (C8), 111.03 (C5), 114.91 (C15), 115.46 (C2), 118.01 (C12), 121.28 (C21), 
122.06 (C8), 122.70 (C9), 124.44 (C14), 127.30 (C17), 127.67 (C20), 128.01 (C4), 130.20 (C18), 130.51 
(C19), 143.20 (C11), 144.9 (C3), 149.20 (C6), 151.70 (C10), 151.17 (C16), 152.37 (C7), 167.00 (C = O). 
EIMS: m/z 559.0458  [M + Na]+, Calcd. for C26H23Cl3O6: 559.0449. 
4.1.5.2. 4-(5-chloro-2-(2,4-dichlorophenoxy)phenoxy)butyl (E)-3-(3,4-dimethoxyphenyl)prop-2-enoate 
(27). Yield  40%  (0.36 mmol,  200 mg);  pale yellow oil; IR (KBr, cm-1): vmax  2935 (C-H),  1706 
(C=O), 1633 (C=C), 1513 (C=CAr), 1260 (C-O-C), 1159 ((C=O)-O), 807 (C-HAr), 701 (C-Cl). 1H-NMR 
(CDCl3, 300 MHz): δ 1.51–1.59 (CH2, m), 1.66–1.74 (CH2, m), 3.84 (2OCH3), 3.90 (-CH2O-, t, J = 6.1 
Hz), 4.07 (-CH2O-, t, J = 6.4 Hz), 6.22 (H2, d, J = 16.0 Hz), 6.57 (H12, d, J = 8.8 Hz), 6.80 (H8, d, J = 
8.4 Hz), 6.85 (H13, dd, J = 8.8, 2.0), 6.86 (H15, d, J = 2.0), 6.96-7.06 (H9, H5, H20, H21, m), 7.35 (H18, d, 
J = 2.3 Hz), 7.54 (H3, d, J = 16.0 Hz); 13C-NMR (CDCl3, 75 MHz): δ 25.10 (CH2), 25.64 (CH2), 55.90 
(OCH3), 55.97 (OCH3), 63.68 (-OCH2-), 68.45 (-OCH2-), 109.68 (C8), 111.08 (C5), 114.81 (C15), 
115.75 (C2), 117.75 (C12), 121.10 (C21), 122.22 (C8), 122.52 (C9), 124.36 (C14), 127.42 (C17), 127.54 
(C20), 127.80 (C4), 130.19 (C18), 130.62 (C19), 143.03 (C11), 144.67 (C3), 149.23 (C6), 151.83 (C10), 
151.14 (C16), 152.61 (C7), 167.10 (C = O). EIMS: m/z 573.0614  [M + Na]+, Calcd. for C27H25Cl3O6: 
573.0604. 
4.1.5.3. 7-(5-chloro-2-(2,4-dichlorophenoxy)phenoxy)heptyl (E)-3-(3,4-dimethoxyphenyl)prop-2-enoate 
(28). Yield  60%  (0.54 mmol,  321 mg);  pale yellow solid; m.p. 63-65 °C; IR (KBr, cm-1): vmax  2934 
(C-H),  1708 (C=O), 1632 (C=C), 1510 (C=CAr), 1258 (C-O-C), 1159 ((C=O)-O), 807 (C-HAr),  753 
(C-Cl). 1H-NMR (CDCl3, 300 MHz): δ 1.14–1.27 (CH2, m), 1.27–1.36 (CH2, m), 1.36–1.46 (CH2, m), 
1.54–1.65 (CH2, m), 1.66–1.75 (CH2, m), 3.89 (2OCH3), 3.90 (-CH2O-, t, J = 6.4 Hz), 4.20 (-CH2O-, t, 
J = 6.7 Hz), 6.32 (H2, d, J = 16.0 Hz), 6.61 (H12, d, J = 8.8 Hz), 6.86 (H8, d, J = 8.7 Hz), 6.91 (H13, dd, 
J = 8.8, 2.3), 6.94 (H15, d, J = 2.3), 6.97 (H21, d, J = 8.5), 7.06 (H5, d, J = 2.6 Hz), 7.07 (H9, dd, J = 8.7, 
2.6 Hz), 7.10 (H20, dd, J = 8.5, 2.5 Hz), 7.43 (H18, d, J = 2.5 Hz), 7.63 (H3, d, J = 16.0 Hz); 13C-NMR 
(CDCl3, 75 MHz): δ 25.60 (CH2), 25.82 (CH2), 28.64 (CH2), 28.83 (2CH2), 55.85 (OCH3), 55.92 
(OCH3), 64.41 (-OCH2-), 68.93 (-OCH2-), 109.65 (C8), 111.04 (C5), 114.65 (C15), 115.96 (C2), 117.57 
(C12), 120.81 (C21), 122.26 (C8), 122.52 (C9), 124.20 (C14), 127.44 (C17), 127.43 (C20), 127.58 (C4), 
130.02 (C18), 130.63 (C19), 142.84 (C11), 144.43 (C3), 149.20 (C6), 151.01 (C10), 151.06 (C16), 152.65 
(C7), 167.21 (C = O). EIMS: m/z 615.1084  [M + Na]+, Calcd. for C30H31Cl3O6: 615.1086. 
4.1.5.4. 9-(5-chloro-2-(2,4-dichlorophenoxy)phenoxy)nonyl (E)-3-(3,4-dimethoxyphenyl)prop-2-enoate 
(29). Yield  40%  (0.36 mmol,  224 mg);  pale yellow oil; IR (KBr, cm-1): vmax  2932 (C-H),  1705 
(C=O), 1633 (C=C), 1513 (C=CAr), 1259 (C-O-C), 1139 ((C=O)-O), 808 (C-HAr),  702 (C-Cl). 1H-
NMR (CDCl3, 300 MHz): δ 1.08–1.47 (5CH2, m), 1.54–1.65 (CH2, m), 1.66–1.78 (CH2, m), 3.89 (-
CH2O-, t, J = 6.4 Hz), 3.91 (2OCH3), 4.21 (-CH2O-, t, J = 6.5 Hz), 6.34 (H2, d, J = 16.0 Hz), 6.62 (H12, 
d, J = 8.8 Hz), 6.86 (H8, d, J = 8.3 Hz), 6.91 (H13, dd, J = 8.8, 2.2), 6.95 (H15, d, J = 2.2), 6.98 (H21, d, J 
= 8.5), 7.04-7.10 (H5, H9, m), 7.11 (H20, dd, J = 8.5, 2.1 Hz), 7.42 (H18, d, J = 2.5 Hz), 7.64 (H3, d, J = 
16.0 Hz); 13C-NMR (CDCl3, 75 MHz): δ 25.71 (CH2), 25.99 (CH2), 28.77 (CH2), 28.91 (CH2), 29.16 
(CH2), 29.21 (CH2), 29.41 (CH2), 55.85 (OCH3), 55.94 (OCH3), 64.58 (-OCH2-), 68.93 (-OCH2-), 
109.54 (C8), 111.00 (C5), 114.55 (C15), 115.95 (C2), 117.54 (C12), 120.78 (C21), 122.38 (C8), 122.61 
(C9), 124.15 (C14), 127.42 (C17), 127.49 (C20), 127.54 (C4), 130.03 (C18), 130.70 (C19), 142.75 (C11), 
144.51 (C3), 149.17 (C6), 151.05 (C10), 151.09 (C16), 152.71 (C7), 167.33 (C = O). EIMS: m/z 643.1397  
[M + Na]+, Calcd. for C32H35Cl3O6: 643.1382. 
4.1.6. 3-(5-chloro-2-(2,4-dichlorophenoxy)phenoxy)propyl 3-(3,4-dimethoxyphenyl)propanoate (30) 
A solution of 26 (100 mg, 0.185 mmol) in metanol was added under hydrogen to a suspention of Pd-C 
10% (5mg) in dry metanol (10 mL). The reaction was monitored by NMR until consumption of the 
starting material. Filtration afforded compound 30 (90.2 mg, 0.167 mmol, 94 %). 
Pale yellow oil; IR (KBr, cm-1): vmax  2935 (C-H),  1735 (C=O), 1498 (C=CAr), 1263 (C-O-C), 1157 
((C=O)-O), 804 (C-HAr), 763 (C-Cl). 1H-NMR (CDCl3, 300 MHz): δ 1.90-1.97 (CH2, m), 2.60 (H2, t, J 
= 7.9 Hz), 2.89 (H3, t, J = 7.9 Hz), 3.85 (OCH3), 3.87 (OCH3), 3.95 (-CH2O-, t, J = 6.2 Hz), 4.05 (-
CH2O-, t, J = 6.2 Hz), 6.65 (H12, d, J = 8.8 Hz), 6.71-6.75  (H8, H13, H15, m), 6.79 (H21, d, J = 8.8 Hz), 
6.92 – 6.97 (H9, H5, m), 7.08 (H20, dd, J = 8.8, 2.4 Hz), 7.43 (H18, d, J = 2.4 Hz); 13C-NMR (CDCl3, 75 
MHz): δ 28.47 (CH2), 30.55 (C3), 35.98 (C2), 55.83 (OCH3), 55.92 (OCH3), 60.65 (-OCH2-), 65.57 (-
OCH2-), 111.35 (C8), 111.07 (C5), 114.92 (C15), 118.01 (C12), 120.08 (C21), 121.30 (C8), 122.00 (C9), 
124.49 (C14), 127.60 (C17), 128.00 (C20), 130.18 (C4), 130.47 (C18), 133.03 (C19), 143.23 (C11), 147.55 
(C6), 148.92 (C10), 150.62 (C16), 152.34 (C7), 172.64 (C = O). EIMS: m/z 561.0614 [M + Na]+, Calcd. 
for C26H25Cl3O6: 561.0618. 
4.2. Biological activity assays 
The compounds were subjected to in vitro evaluation as regards their cytotoxicity, anti-leishmanial and 
anti-trypanosomal activity against U-937 human cells and against intracellular amastigotes of L. (V) 
panamensis and T. cruzi, respectively. 
4.2.1. In vitro Cytotoxicity  
The cytotoxic activity of the compounds was assessed based on the viability of the human 
promonocytic cell line U-937 (ATCC CRL-1593.2TM) evaluated by the MTT (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide) assay following the methodology described previously [48]. 
Briefly, cells grown in tissue flasks were harvested and washed with phosphate buffered saline (PBS) 
by centrifuging. Cells were counted and adjusted at 1 ×106 cells/mL of RPMI-1640 supplemented with 
complete 10% Fetal Bovine Serum (FBS) and 1% antibiotics (100 U/mL penicillin and 0.1 mg/mL 
streptomycin). One hundred µL were dispensed into each well of a 96-well cell-culture plate and then 
100 mL of RPMI-1640 and the corresponding concentrations of the compounds were added, starting at 
200 µg/mL in duplicate. Plates were incubated at 37 °C, 5% CO2 during 72 h in the presence of 
compound. The effect of compounds was determined by measuring the activity of the mitochondrial 
dehydrogenase by adding 10 µL/well of MTT solution (0.5 mg/mL) and incubation at 37 °C for 3h. 
The reaction was stopped by adding 100 µL/well of 50% isopropanol solution with 10% sodium 
dodecyl sulfate and 30 min incubation. Cell viability was determined based on the quantity of formazan 
produced  according to the intensity of color (absorbance) registered as optical densities (O.D) obtained 
at 570 nm in a spectrophotometer (Varioskan™ Flash Multimode Reader - Thermo Scientific, USA). 
Cells cultured in absence of compounds were used as control of viability (negative control), while 
amphotericin B (AmB) was used as control for cytotoxicity (non-cytotoxic and cytotoxic drugs, 
respectively). Assays were conducted in two independent runs with three replicates per each 
concentration tested. 
 
4.2.2. In vitro anti-leishmanial activity 
The activity of compounds was evaluated on intracellular amastigotes of L. (V) panamensis transfected 
with the green fluorescent protein gene (MHOM/CO/87/UA140pIR-GFP) [49]. The effect of each 
compound was determined according to the inhibition of the infection evidenced by both decrease of 
the infected cells and decrease of intracellular parasite load. Briefly, U-937 human cells at a 
concentration of 3 × 105 cells/mL in RPMI 1640 and 0.1 μg/mL of phorbol-12-myristate-13-acetate 
(PMA) were dispensed into each well of a 24-well cell culture plate and then infected with 5 days-old 
promastigotes in a 15:1 parasites per cell ratio. Plates were incubated at 34 °C, 5% CO2 during 3 h and 
cells were washed two times with PBS to eliminate not internalized parasites. One mL of fresh RPMI 
1640 supplemented with 10% FBS and 1% antibiotics was added into each well, cells were incubated 
again to guarantee multiplication of intracellular parasites. After 24 h of infection, culture medium was 
replaced by fresh culture medium containing each compound at 20 μg/mL or lower (based on the 
cytotoxicity showed previously by each compound), plates were incubated at 37 °C, 5% CO2. After 72 
h, inhibition of the infection was determined. For this, cells were removed from the bottom plate with a 
trypsin/EDTA (250 mg) solution; recovered cells were centrifuged at 1100 rpm during 10 min at 4 °C, 
the supernatant was discarded and cells were washed with 1 mL of cold PBS and centrifuged at 1100 
rpm during 10 min at 4 °C. The supernatant was discarded and cells were suspended in 500 μL of PBS 
and analyzed by flow cytometry (FC 500MPL, Cytomics, Brea, CA, US. All determinations for each 
compound and standard drugs were carried out in triplicate, in two independent experiments (Buckner 
et al., 1996; Pulido et al., 2012). Activity of the tested compounds was carried out in parallel with 
infection progress in culture medium alone and in culture medium with AmB as anti-leishmanial drugs 
(positive controls). Compounds that showed percentages of inhibition higher than 50% to 20 or fewer 
μg/mL were then evaluated at four additional concentrations to determine the  effective concentration 
50 (EC50). Here, infected cells were exposed against each concentration of compounds during 72 h; 
then, cells were removed and tested by flow cytometry as described before.  
4.2.3. In vitro anti-trypanosomal activity  
Compounds were tested on intracellular amastigotes of T. cruzi, Tulahuen strain transfected with β-
galactosidase gene (donated by Dr. F. S. Buckner, University of Washington) [50]. The activity was 
determined according to the ability of the compounds to reduce the infection of U-937 cells by T. cruzi. 
Following the procedure described above, anti-parasite activity was initially screened at a single 
concentration of 20 mg/mL. In this case, 100 μL of U-937 human cells at a concentration of 2.5 × 105 
cells/mL in RPMI-1640, 10% SFB and 0.1 μg/mL of PMA were placed in each well of  96-well plates 
and then infected with phase growth epimastigotes in 5:1 (parasites per cell) ratio and incubated at 34 
°C, 5% CO2. After 24 hours of incubation, 20 μg/mL of each compounds were added to infected cells. 
After 72 h of incubation, the effect of all compounds on the viability of intracellular amastigotes was 
determined by measuring the β-galactosidase activity by spectrophotometry adding 100 μM CPRG and 
0.1% nonidet P-40 to each well. After 3 h of incubation, plates were read at 570 nm in a 
spectrophotometer (Varioskan™ Flash Multimode Reader - Thermo Scientific, USA) and intensity of 
color (absorbance) was registered as O.D. compounds that showed inhibition percentages higher than 
50% were evaluated again at four concentrations selected according to the LC50 previously obtained for 
each compound. Infected cells exposed to benznidazol (BNZ) were used as control for anti-
trypanosomal activity (positive control) while infected cells incubated in culture medium alone were 
used as control for infection (negative control). Non-specific absorbance was corrected by subtracting 
the O.D of the blank. Determinations were done by triplicate in at least two independent experiments 
[51]. 
4.2.4. Statistical Analysis  
Cytotoxicity was determined according to viability and mortality percentages obtained for each 
isolated experiment (compounds, amphotericin B, Benznidazole and culture medium alone). The 
results were expressed as 50 lethal concentrations (LC50) that corresponds to the concentration 
necessary to eliminate 50% of cells and calculated by Probit analysis [52]. Percentage of viability was 
calculated by Equation 1, where the O.D of control, corresponds to 100% of viability. In turn, mortality 
percentage corresponds to 100%–% viability:  
% Viability = (O.D Exposed cells) / (O.D Control cells) × 100 (1) 
The degree of toxicity was graded according to the LC50 value using the following scale: high 
cytotoxicity: LC50 < 200 μM; moderate cytotoxicity: LC50 in the 200-300 μM range, and potentially 
non-cytotoxicity: LC50 > 300 μM. 
Anti-leishmanial activity was determined according to the percentage of infected cells and parasite 
load obtained for each experimental condition by flow cytometry. The percentage of infected cells was 
determined as the number of positive events by double fluorescence (green for parasites and red for 
cells) using dotplot analysis. On the other hand, the parasitic load was determined by analysis of mean 
fluorescence intensity (MFI) of fluorescent parasites [48]. The parasite inhibition was calculated by 
equation 2, where the MFI of control, corresponds to 100% of parasites. In turn, inhibition percentage 
corresponds to 100% – % Parasites. Results of anti-leishmanial activity were expressed as EC50 
determined by the Probit method [52]:  
% Parasite = (MFI Exposed parasites) / (MFI Control parasites) × 100 (2) 
Similarly, anti-trypanosomal activity was determined according to the percentage of infected cells 
and parasite load obtained for each experimental condition by colorimetry. The parasite inhibition was 
calculated by equation 3, where the O.D of control corresponds to 100% of parasites. In turn, the 
inhibition percentage corresponds to 100% – % Parasites. Results of anti-trypanosomal activity were 
also expressed as EC50 determined by the Probit method [52]:  
% Parasite = (O.D Exposed parasites) / (O.D Control parasites) × 100 (3) 
     The anti-leishmanial or anti-trypanosomal activities were graded according to the EC50 value using 
the following scale: High activity: EC50 < 40 μM, moderate activity: EC50 in the 40-80 μM range, 
potentially non activity: EC50 > 80 μM. 
The selectivity index (SI), was calculated by dividing the cytotoxic activity and the anti-leishmanial 
or anti-trypanosomal activity using the following formula: SI = CL50/CE50. Cytotoxic compound: 
LC50<100 µg/mL.  
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